Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar, Bonny B. Morris, Rodwige Desnoyer, Heidi D. Klepin, Keyanoosh Hosseinzadeh, Clancy Clark, Amy Cameron, John Leyendecker, Ralph D'Agostino, Umit Topaloglu, Lakmal W. Boteju, Asela R. Boteju, Rob Shorr, Zuzana Zachar, Paul M. Bingham, Tamjeed Ahmed, Sandrine Crane, Riddhishkumar Shah, John J. Migliano, Timothy S. PardeeLance Miller, Gregory Hawkins, Guangxu Jin, Wei Zhang, Boris Pasche
Dive into the research topics of 'Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial'. Together they form a unique fingerprint.